Coombs-Negative Autoimmune Hemolytic Anemia Associated With Liver Cirrhosis Due to Hepatitis C Virus

Mikiko Okazakia, Takakazu Higuchib, e, Ryosuke Koyamadab, Sadamu Okadab, Yoshiyuki Fujitac, Toyomi Kamesakid

Abstract

An 83-year-old woman who had been treated for liver cirrhosis due to hepatitis C virus (HCV) had progressive thrombocytopenia and anemia. Coombs-negative autoimmune hemolytic anemia (AIHA) was diagnosed based on the findings of hemolysis and the increased number of the red blood cell-bound immunoglobulin G molecules. The increased level of the platelet-associated immunoglobulin G and refractoriness to platelet transfusions suggested involvement of autoimmune mechanism in the thrombocytopenia. Oral prednisolone was effective for AIHA and thrombocytopenia. Global derangement of the immune system associated with HCV was suggested. As increased serum bilirubin and lactate dehydrogenase levels are common laboratory findings in patients with chronic HCV liver diseases, it is likely that a considerable number of patients complicated with Coombs-negative AIHA, which is a medically treatable anemia, are left without being noticed.

Keywords: Hepatitis C virus; Liver cirrhosis; Autoimmune hemolytic anemia; Coombs test

Introduction

Hepatitis C virus (HCV) infection not only causes chronic liver diseases but is frequently associated with extrahepatic autoimmune manifestations [1-4]. The clinical significance of such autoimmune phenomena is highly diverse, ranging from subclinical or laboratory abnormalities to overt clinical manifestations that can be severe in some patients. Immune thrombocytopenia is reported to be complicated in a considerable number of patients with chronic HCV infection [5-10]; however, the frequency and the significance of the complication of autoimmune hemolytic anemia (AIHA) have never been extensively studied [11].

We herein report a case of liver cirrhosis due to chronic HCV infection complicated with Coombs-negative AIHA, which is a medically treatable anemia but may be left unrecognized in patients with HCV chronic liver diseases.

Case Report

An 83-year-old woman had been treated at St. Luke’s International Hospital and her family physician for liver cirrhosis due to chronic HCV infection possibly infected when she had a blood transfusion at delivery 54 years earlier. She had not received interferon therapy or any other antiviral agents and been treated with ursodeoxycholic acid. Hepatocellular carcinoma (HCC) had been detected 4 years earlier and treated with transcatheter arterial embolization and radiofrequency ablations. She had been diagnosed as essential tremor, hypothyroidism, and type 2 diabetes and taking medications for these complications. There was no family history of autoimmune diseases. She had a blood test 2 weeks before admission and the platelet count was 119 × 10⁹/L. Several days later, she noticed petechiae and purpurae on the extremities which rapidly extended to the trunk and was admitted.

On admission, generalized subcutaneous and oral mucosal hemorrhages were noted. The liver and the spleen were not palpable. The white blood cell count was 3.9 × 10⁹/L, the red blood cell (RBC) count was 2.87 × 10¹²/L with 6.1% of reticulocytes, the hemoglobin (Hb) level was 10.9 g/dL, and the hematocrit level was 31.2%. The platelets count was 6.0 × 10⁹/L. The blood chemistry showed that the total protein level was 9.1 g/dL, the total bilirubin level was 2.5 mg/dL, the direct bilirubin level was 1.8 mg/dL, and the aspartate transaminase level was 84 U/L, the alanine transaminase level was 55 U/L, and the lactate dehydrogenase (LDH) level was 301 U/L (reference range: 118 - 223). The serum ferritin level was 930 ng/mL and the haptoglobin level was below the limit of detection. The electrophoresis of the serum protein revealed polyclonal increase of the γ-globulin and the serum immunoglobulin (Ig) G level was 4,768 mg/dL. Antinuclear (homogenous type), anti-thyroglobulin, and anti-thyroid peroxidase antibodies

Manuscript accepted for publication April 23, 2015

doi: http://dx.doi.org/10.14740/jh202w
Cytopenias of various degrees are frequently complicated with increase of B lymphocyte activating factor [2-4]. Protein 2 and CD81 on the surface of B lymphocytes and the inhibition of B lymphocytes through the binding of HCV envelop protein 2 and CD81 on the surface of B lymphocytes and the increase of B lymphocyte activating factor [2-4].

On the other hand, it is well recognized that a variety of cytopenias of various degrees are frequently complicated with chronic liver diseases [13]. Thrombocytopenia is the most frequently observed hematological complication and seen in up to 76% of patients [14, 15]. Multiple factors are assumed to contribute to the development of thrombocytopenia, including splenic sequestration, suppression of the production in the bone marrow, and decreased thrombopoietin level [13-15]. Moreover, autoimmune mechanisms are considered to play a role in the pathogenesis of HCV-associated thrombocytopenia. In the present case, involvement of autoimmune mechanism was suggested by the elevated PAIgG level, refractoriness to platelet transfusions, and prompt response to corticosteroid.

Anemia is another common complication of chronic liver diseases [13, 16]. The causes of anemia include acute or chronic gastrointestinal hemorrhage and hypersplenism secondary to portal hypertension. In addition, alterations in the composition of the lipids in the RBC membrane due to the derangement in the lipoprotein metabolism may lead to hemolysis and, in cases of chronic HCV infection, antiviral therapies with ribavirin may cause hemolytic anemia [13, 16]. However, the association between AIHA and chronic HCV infection has not been explored except a cohort study [8] and a case series [11] and the frequency and significance of anti-RBC antibodies causative of Coombs-negative AIHA among patients with chronic HCV liver diseases have never been studied. Considering the high frequency of various autoantibodies among patients with chronic HCV infection, we assume that the frequency of anti-RBC antibodies is substantially high among patients with chronic HCV liver diseases. As the laboratory findings of hemolysis, namely elevated indirect bilirubin and LDH levels, are also common laboratory findings observed in patients with chronic liver diseases, it is highly possible that patients with mild to moderate hemolysis are left unrecognized. Therefore, we believe that autoimmune hemolysis contributes to the development of anemia in a considerable number of patients with chronic HCV liver disease and that the quantitative assay of anti-RBC antibodies should be performed in patients with chronic HCV liver disease. As the laboratory findings of hemolysis, namely elevated indirect bilirubin and LDH levels, are also common laboratory findings observed in patients with chronic liver diseases, it is highly possible that patients with mild to moderate hemolysis are left unrecognized. Therefore, we believe that autoimmune hemolysis contributes to the development of anemia in a considerable number of patients with chronic HCV liver disease and that the quantitative assay of anti-RBC antibodies should be performed in patients with chronic HCV liver disease and anemia, especially when other autoantibodies are detected as global derangement of the immune system associated with HCV may be present in such patients. Awareness of this complication and large studies are definitely needed to elucidate the contribution of this medically treatable anemia to the etiology of anemia seen in patients with chronic HCV liver diseases.

**Discussion**

HCV infection is associated with development of a variety of both non-organ specific and organ specific autoantibodies [1-4]. Diverse mechanisms leading to extrahepatic autoimmune manifestations in chronic HCV infection are proposed, including direct infection of HCV on B lymphocytes leading to their expansion, molecular mimicry between HCV protein and self-antigens, reduction in the T regulatory cell number, and activation of B lymphocytes through the binding of HCV envelope protein 2 and CD81 on the surface of B lymphocytes and the increase of B lymphocyte activating factor [2-4].

On the other hand, it is well recognized that a variety of cytopenias of various degrees are frequently complicated with chronic liver diseases [13]. Thrombocytopenia is the most frequently observed hematological complication and seen in up to 76% of patients [14, 15]. Multiple factors are assumed to contribute to the development of thrombocytopenia, including splenic sequestration, suppression of the production in the bone marrow, and decreased thrombopoietin level [13-15]. Moreover, autoimmune mechanisms are considered to play a role in the pathogenesis of HCV-associated thrombocytopenia. In the present case, involvement of autoimmune mechanism was suggested by the elevated PAIgG level, refractoriness to platelet transfusions, and prompt response to corticosteroid.

Anemia is another common complication of chronic liver diseases [13, 16]. The causes of anemia include acute or chronic gastrointestinal hemorrhage and hypersplenism secondary to portal hypertension. In addition, alterations in the composition of the lipids in the RBC membrane due to the derangement in the lipoprotein metabolism may lead to hemolysis and, in cases of chronic HCV infection, antiviral therapies with ribavirin may cause hemolytic anemia [13, 16]. However, the association between AIHA and chronic HCV infection has not been explored except a cohort study [8] and a case series [11] and the frequency and significance of anti-RBC antibodies causative of Coombs-negative AIHA among patients with chronic HCV liver diseases have never been studied. Considering the high frequency of various autoantibodies among patients with chronic HCV infection, we assume that the frequency of anti-RBC antibodies is substantially high among patients with chronic HCV liver diseases. As the laboratory findings of hemolysis, namely elevated indirect bilirubin and LDH levels, are also common laboratory findings observed in patients with chronic liver diseases, it is highly possible that patients with mild to moderate hemolysis are left unrecognized. Therefore, we believe that autoimmune hemolysis contributes to the development of anemia in a considerable number of patients with chronic HCV liver disease and that the quantitative assay of anti-RBC antibodies should be performed in patients with chronic HCV liver disease and anemia, especially when other autoantibodies are detected as global derangement of the immune system associated with HCV may be present in such patients. Awareness of this complication and large studies are definitely needed to elucidate the contribution of this medically treatable anemia to the etiology of anemia seen in patients with chronic HCV liver diseases.

**References**


4. Ferri C, Antonelli A, Mascia MT, Sebastiani M, Fallahi P,  

**Figure 1.** Clinical course during admission. Changes in the hemoglobin level (Hb, straight line) and the platelet count (Plt, dotted line) and the treatment given are illustrated.


